Cancer Metastasis, a Clinical Dilemma for Therapeutics
Background: More than 90% of cancer deaths are caused by cancer metastasis. Cancer metastatic therapy is a top priority topic. Objective: New therapeutics against cancer metastasis is to be discovered. Methods: In the past pathogenesis study, a therapeutic dilemma has been discovered from literatures of epithelial-mesenchymal cell interchange in late-staged cancer patients-opposite tumor pathogenesis routes between primary and metastatic tumors. Results: Possible options for overcoming this dilemma are enlisted from different therapeutic attempts (such as novel drug target (cancer biomarkers) discovery, antimetastatic drug developments, biotherapies, drug combinations, cancer therapeutics according to metastatic cascades, different types of personalized medicine paradigms and so on). Conclusions: These therapeutic options might change the landscape of cancer treatments and managements in clinics forever..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Current drug therapy - 11(2016), 2, Seite 163-169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Da-Yong Lu [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.2174/1574885511666160810143216 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1986443116 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1986443116 | ||
| 003 | DE-627 | ||
| 005 | 20230509073653.0 | ||
| 007 | tu | ||
| 008 | 161202s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1574885511666160810143216 |2 doi | |
| 028 | 5 | 2 | |a PQ20161201 |
| 035 | |a (DE-627)OLC1986443116 | ||
| 035 | |a (DE-599)GBVOLC1986443116 | ||
| 035 | |a (PRQ)b1756-c8eb524b65366aa40683f16e0bf7861e5645895db3a49d1dc5f066b43f414afd0 | ||
| 035 | |a (KEY)0598958220160000011000200163cancermetastasisaclinicaldilemmafortherapeutics | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 100 | 0 | |a Da-Yong Lu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer Metastasis, a Clinical Dilemma for Therapeutics |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Background: More than 90% of cancer deaths are caused by cancer metastasis. Cancer metastatic therapy is a top priority topic. Objective: New therapeutics against cancer metastasis is to be discovered. Methods: In the past pathogenesis study, a therapeutic dilemma has been discovered from literatures of epithelial-mesenchymal cell interchange in late-staged cancer patients-opposite tumor pathogenesis routes between primary and metastatic tumors. Results: Possible options for overcoming this dilemma are enlisted from different therapeutic attempts (such as novel drug target (cancer biomarkers) discovery, antimetastatic drug developments, biotherapies, drug combinations, cancer therapeutics according to metastatic cascades, different types of personalized medicine paradigms and so on). Conclusions: These therapeutic options might change the landscape of cancer treatments and managements in clinics forever. | ||
| 700 | 0 | |a Ting-Ren Lu |4 oth | |
| 700 | 0 | |a Bin Xu |4 oth | |
| 700 | 0 | |a Rong-Xin Qi |4 oth | |
| 700 | 0 | |a Nagendra S. Yarla |4 oth | |
| 700 | 0 | |a Xiao-Die Zhou |4 oth | |
| 700 | 0 | |a Jian Ding |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug therapy |d [S.l.] : Bentham Science, 2006 |g 11(2016), 2, Seite 163-169 |w (DE-627)527561886 |w (DE-600)2274490-3 |w (DE-576)435514210 |x 1574-8855 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2016 |g number:2 |g pages:163-169 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.2174/1574885511666160810143216 |3 Volltext |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1574-8855&volume=11&issue=2&spage=163 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2016 |e 2 |h 163-169 | ||